Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Cancer|September 17, 2014
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AMLJorge E Cortes, Stuart L Goldberg, Eric J Feldman, et al.
Leukemia Research|August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles, Eric J Feldman, Gail J Roboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemiaGail J Roboz, Francis J Giles, Ellen K Ritchie, et al.
Cancer Chemotherapy and Pharmacology|August 17, 2013
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemiasIvana Gojo, Mariola Sadowska, Alison Walker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphomaJohn D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Transplantation and Cellular Therapy|February 28, 2024
Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant CohortM Bakri Hammami, Jhannine Alyssa Verceles, Mendel Goldfinger, et al.
Blood|May 27, 2011
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AMLJoseph M Scandura, Gail J Roboz, Michelle Moh, et al.
Leukemia & Lymphoma|August 25, 2012
Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignanciesMichael J Satlin, David P Calfee, Liang Chen, et al.
Blood|April 2, 2014
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLJeffrey E Lancet, Jorge E Cortes, Donna E Hogge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2023
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AMLDavid Levitz, Yogen Saunthararajah, Kateryna Fedorov, et al.
Pageof 5